Cart
sales@molnova.com
WHI-P131
CAS No. 202475-60-3
WHI-P131( Janex 1 )
Catalog No. M13153 CAS No. 202475-60-3
Janex-1 is a cell-permeable, reversible, potent, ATP-competitive, and specific inhibitor of JAK3.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 50 | In Stock |
|
| 2MG | 29 | In Stock |
|
| 5MG | 46 | In Stock |
|
| 10MG | 77 | In Stock |
|
| 25MG | 130 | In Stock |
|
| 50MG | 184 | In Stock |
|
| 100MG | 276 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameWHI-P131
-
NoteResearch use only, not for human use.
-
Brief DescriptionJanex-1 is a cell-permeable, reversible, potent, ATP-competitive, and specific inhibitor of JAK3.
-
DescriptionJanex-1 is a cell-permeable, reversible, potent, ATP-competitive, and specific inhibitor of JAK3 (IC50 = 78μM); has no effect on JAK1, JAK2, or Zap/Syk or SRC tyrosine kinases.
-
In Vitro——
-
In Vivo——
-
SynonymsJanex 1
-
PathwayAngiogenesis
-
TargetJAK
-
RecptorJAK3| JAK3
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number202475-60-3
-
Formula Weight297.31
-
Molecular FormulaC16H15N3O3
-
Purity>98% (HPLC)
-
SolubilityDMSO: 10 mM
-
SMILESOC1=CC=C(NC2=C3C=C(OC)C(OC)=CC3=NC=N2)C=C1
-
Chemical Name4-[(6,7-dimethoxy-4-quinazolinyl)amino]-phenol
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
PF-06651600
PF-06651600 is a novel potent, selective JAK3 inhibitor with IC50 of 0.346 nM, displays >1,000-fold selectivity over JAK1 and JAK2; inhibits Th1 and Th17 cell differentiation and function, reduces disease pathology in rat adjuvant-induced arthritis as well as in mouse experimental autoimmune encephalomyelitis models; selectively targets γc cytokine pathways while preserving JAK1-dependent anti-inflammatory signaling such as the IL-10 suppressive functions following LPS treatment in macrophages and the suppression of TNFα and IL-1β production in IL-27-primed macrophages.Rheumatoid ArthritisPhase 2 Clinical
-
Solcitinib
A potent, selective JAK1 inhibitor for the treatment of psoriasis, lupus, and ulcerative colitis.
-
Lorpucitinib
Lorpucitinib (JNJ-64251330) is an orally available, selective and potent JAK kinase inhibitor for the study of inflammatory and gastrointestinal disorders associated with Janus kinase (JAK) signaling.
